Image 4_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff by M. Firoz Mian (10013314)

“…</p>Results<p>E2-treated WT OVX immunized mice after intravaginal HSV-2 challenge showed significantly increased HSV-2-specific IgG2b and IgG2c antibodies in serum and vaginal secretions compared to placebo mice and enhanced B220-CD138+ IgG2c+ plasma cells within the nasal mucosa and vaginal tract 6-weeks after immunization. …”

The Effect of Chronic Stress on Apoptosis Regulation and Oncogenesis Evolution: A Theoretical Approach. by DIMITRIOS KIMOGLOU (20499350)

“…In particular, we seek to illustrate the epigenetic influence of stress on genes that control apoptosis, as well as the significance of the HPA axis as a therapeutic target for restoring cellular equilibrium. …”

Data Sheet 1_Efficacy and safety of Tongxinluo capsules combined with conventional therapy for acute myocardial infarction: a systematic review and meta-analysis.zip by Dan Ouyang (554436)

“…The meta-analysis revealed that Tongxinluo capsule combined with conventional treatment significantly decreased the 1-month MACCE rate (RR = 0.62, 95% CI 0.47 to 0.81; p = 0.0007), along with the individual risks of 1-month MACCE, including cardiac death (RR = 0.68, 95% CI 0.50 to 0.93; p = 0.02) and myocardial reinfarction (RR = 0.11, 95% CI 0.01 to 0.94; p = 0.04). …”

Data Sheet 2_Efficacy and safety of Tongxinluo capsules combined with conventional therapy for acute myocardial infarction: a systematic review and meta-analysis.zip by Dan Ouyang (554436)

“…The meta-analysis revealed that Tongxinluo capsule combined with conventional treatment significantly decreased the 1-month MACCE rate (RR = 0.62, 95% CI 0.47 to 0.81; p = 0.0007), along with the individual risks of 1-month MACCE, including cardiac death (RR = 0.68, 95% CI 0.50 to 0.93; p = 0.02) and myocardial reinfarction (RR = 0.11, 95% CI 0.01 to 0.94; p = 0.04). …”

Table 3_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Table 4_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Image 2_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.jpeg by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Table 5_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Table 1_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Table 7_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Image 9_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.jpeg by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Image 1_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.jpeg by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Table 8_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Image 8_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.jpeg by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Table 9_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Table 6_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Table 2_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.xlsx by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Image 6_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.jpeg by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Image 5_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.jpeg by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”

Image 4_Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.jpeg by Melisa Gualdrón-López (5445410)

“…Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). …”